These findings differ from reports from In et al., who analyzed 15 cSCC patients treated with PD-1 inhibitor and reported 1 responder with an MLH1 mutation and another responder with an MSH6 mutation. The gene discussed is MLH1; the disease is skin squamous cell carcinoma.